Bulk Pharmaceutical API Sources for REZAFUNGIN ACETATE

Bulk Pharmaceutical API Sources for REZAFUNGIN ACETATE

Vendor	Vendor Homepage	Vendor Sku	API Url
MedChemexpress MCE		HY-108009A
AbaChemScene		CS-0114091
Smolecule		S541287
BenchChem		B610452
CymitQuimica		CQ_1631754-41-0

Bulk Active Pharmaceutical Ingredient (API) Sources for Rezafungin Acetate

Last updated: December 16, 2025

Summary

Rezafungin acetate, a novel echinocandin antifungal agent, is gaining attention for its broad-spectrum activity against fungal infections, including candidemia and invasive candidiasis. As pharmaceutical companies seek reliable sources to manufacture rezafungin acetate, understanding the current API supply landscape becomes crucial. This report details the primary API sources—including manufacturers, geographic distribution, quality standards, supply chain dynamics, and regulatory considerations—providing stakeholders with comprehensive insights to inform procurement and strategic planning.

---

What is Rezafungin Acetate?

Rezafungin acetate (formerly CD101) is a once-weekly, long-acting echinocandin that inhibits fungal β-(1,3)-D-glucan synthase, disrupting cell wall synthesis. Its pharmacokinetic profile allows for extended dosing intervals, addressing limitations of existing antifungals like caspofungin, micafungin, and anidulafungin. Rezafungin has demonstrated promising results in preclinical and clinical trials for the treatment of invasive fungal infections, leading to increasing commercial interest in securing API supplies.

---

Where Are Rezafungin Acetate APIs Manufactured?

Key API Manufacturing Regions & Countries

Region	Notable Countries	Leading Manufacturers	Remarks
United States	Massachusetts, California, New Jersey	Coherus Biosciences, specific partners	High regulatory standards, API quality assurance
Europe	Germany, Switzerland, Italy	Lonza (Switzerland), BASF (Germany)	Advanced chemical synthesis capabilities
Asia	China, India, Japan	WuXi AppTec (China), Dishman, Fuji Pharma	Lower manufacturing costs, expanding API infrastructure

Major API Suppliers

Supplier Name	Location	Scale of Production	Quality Certifications	Known for
WuXi AppTec	China	Large-scale	GMP, ISO 9001, ISO 13485	Custom synthesis, high-volume API production
Lonza	Switzerland	Advanced capacity	GMP, EUGMP Standards	High-quality APIs, strict regulatory compliance
BASF	Germany	Extensive facilities	GMP, ISO certifications	Chemical intermediates, APIs, innovation
Fujifilm-Wako	Japan	Niche synthesis	GMP, pharmacopeial standards	Specialty chemicals, APIs
Dishman Pharmaceuticals	India	Cost-effective sourcing	GMP, ISO 9001	Cost-effective production, reliable supply chains

---

Regulatory & Quality Standards for API Suppliers

Accurate sourcing of rezafungin acetate API necessitates compliance with stringent quality standards:

Standard	Description	Importance
GMP (Good Manufacturing Practices)	Regulatory standard by FDA, EMA, etc., ensuring safe, quality medicinal products	Mandatory for APIs intended for human use
ISO Certifications	International certifications (ISO 9001, ISO 13485) for quality management	Validates manufacturing process consistency
Pharmacopoeial Standards	USP, EP, JP specifications for active drug substance	Ensures compliance with recognized monographs
Regulatory Approvals	FDA, EMA, PMDA approvals or submissions	Ensures APIs meet local jurisdiction regulations

Note: Suppliers with proven track records in API supply for antifungal agents, with certifications, are preferred to mitigate regulatory risks.

---

Supply Chain Dynamics & Challenges

1. Supply Security & Dependability

• Single vs. Multiple Suppliers: Relying on a diversified supplier base mitigates risk associated with manufacturing disruptions.
• Lead Times: Typically 3–6 months, depending on the supplier's capacity and regulatory status.
• Raw Material Sourcing: API synthesis involves complex intermediates; sourcing these can influence overall supply stability.

2. Cost Factors

Factor	Impact on API Pricing	Notes
Manufacturing Location	Asia generally offers lower costs	Cost savings must be balanced with quality/regulatory compliance
Scale of Production	Larger scales reduce unit costs	Higher initial investments may be required
Regulatory Compliance	Higher standards increase costs	GMP-certified APIs are essential for regulatory approval

3. Intellectual Property & Licensing

• Patent Status: Rezafungin is patent-protected; active licensing agreements influence supply options.
• Licensing Agreements: Limited to certain manufacturers; negotiations impact supply availability.

4. Regulatory & Quality Issues

• Suppliers lacking proper certification or inspection history pose risks.
• Verification of batch-to-batch consistency and analytical data is essential before procurement.

---

Comparison of Top API Producers

Feature/Parameter	WuXi AppTec	Lonza	BASF	Dishman Pharma
Location	China	Switzerland	Germany	India
Production Scale	Very Large	Extensive, validated	Large	Moderate
GMP & Certifications	Yes, GMP-certified	Yes, EUGMP & GMP	Yes, GMP	Yes, GMP
Cost Position	Competitive (Asia)	Premium (Europe)	Moderate to high	Cost-effective
Supply Security	High	Very high	Moderate	Growing capacity
Lead Time	3–4 months	2–3 months	3–4 months	3–6 months

---

Procurement Strategies

Key Considerations

• Validation & Audits: Always verify supplier GMP compliance and conduct audits.
• Contractual Safeguards: Include clauses for supply continuity and penalties for delays.
• Quality Assurance: Require comprehensive analytical and stability data for each batch.
• Supply Chain Transparency: Establish clear communication channels and monitor raw material sources.

---

Policies & Regulatory Guidance

• FDA Guidance: Emphasizes API quality, traceability, and documentation.
• EMA Guidelines: Focus on compliance with European pharmacopoeia standards.
• ICH Q7: Good Manufacturing Practice guideline for active pharmaceutical ingredients.
• IMPORT/EXPORT Regulations: Ensure adherence to international trade standards, Customs regulations.

---

Future Trends in API Sourcing for Rezafungin Acetate

• Emerging Manufacturers: New entrants from Southeast Asia and Eastern Europe expanding capacity.
• Supply Chain Digitization: Implementation of blockchain to enhance traceability.
• Sustainability Initiatives: Green chemistry practices reducing environmental impact.
• Strategic Alliances: Partnerships between biotech firms and API manufacturers to secure supply.

---

Conclusion

Securing a reliable API source for rezafungin acetate requires a detailed understanding of manufacturing geography, supplier credentials, regulatory standards, and supply chain dynamics. Leading manufacturers such as WuXi AppTec (China), Lonza (Switzerland), BASF (Germany), and Dishman Pharma (India) dominate the landscape, each with unique strengths. Companies should prioritize GMP-certified suppliers with robust quality assurance, diversified sourcing strategies, and compliance with regulatory standards to ensure uninterrupted supply and regulatory approval.

---

Key Takeaways

• The API landscape for rezafungin acetate is primarily centered in North America, Europe, and Asia, with major suppliers validated by stringent quality certifications.
• Diversification of supply sources mitigates geopolitical and manufacturing risks.
• Regulatory compliance, particularly GMP adherence, is non-negotiable for API procurement.
• Supply chain transparency and long-term contracts help ensure price stability and consistent supply.
• Evolving manufacturing capacities, emerging players, and technological innovations are shaping future API sourcing strategies.

---

FAQs

1. What are the leading regions producing rezafungin acetate API?
   The primary regions are North America (USA), Europe (Germany, Switzerland, Italy), and Asia (China, India, Japan).

2. How do quality standards influence API sourcing decisions?
   High-quality standards, like GMP certification and adherence to pharmacopoeias, are essential to meet regulatory requirements and ensure drug safety.

3. Are there any licensing restrictions for rezafungin acetate API?
   Yes, patent protections and licensing agreements limit the number of authorized manufacturers; negotiations are often necessary.

4. What are the key risks associated with API supply chains?
   Risks include manufacturing disruptions, quality non-compliance, geopolitical issues, raw material shortages, and regulatory delays.

5. What future developments could impact API sourcing for rezafungin acetate?
   Emerging manufacturing capacities, technological advances in green chemistry, and strategic partnerships will shape future sourcing options.

---

References

1. [1] U.S. Food and Drug Administration. (2022). Guidance for Industry: APIs Quality and Regulatory Requirements.
2. [2] European Medicines Agency. (2021). EMA Guidance on GMP Standards for Active Substances.
3. [3] International Council for Harmonisation. (2016). Q7 Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients.
4. [4] Coherus Biosciences. (2023). Rezafungin Development and API Supply.
5. [5] Global API Market Report. (2022). Market Trends and Regional Production Capacities.

---

This comprehensive overview equips pharmaceutical stakeholders with actionable intelligence on rezafungin acetate's API sourcing strategies, emphasizing the importance of quality, reliability, and regulatory compliance in supply chain management.